Interviews

C. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.

Nancy U. Lin, MD, discusses how she would use the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine now that it has been approved for treatment of patients with HER2-positive metastatic breast cancer.

Ruben Mesa, MD, shares highlights from his presentation on the role of JAK inhibitors in myelofibrosis during the first annual Texas Virtual MPN Workshop and Meeting.

Bruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.

Noopur S. Raje, MD, discusses the results of the BOSTON trial of selinexor, bortezomib, and dexamethasone in patients with multiple myeloma.

Ulka Vaishampayan, MD, discusses the use of tivozanib as treatment of patients with advanced renal cell carcinoma, based on supportive data in the TIVO-3 clinical trial.

John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.

Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.

Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.

Vivek Subbiah, MD, discusses the implications of the phase 1/2 LIBRETTO-001 study, which evaluated selpercatinib as treatment of patients with RET fusion-positive non–small cell lung cancer.

Kami J. Maddocks, MD, discusses the use of Bruton’s tyrosine kinase inhibitors in patients with B-cell malignancies and how that may change in the future to provide more treatment options for these patients.

Thomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Michael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study.

Nilanjan Ghosh, MD, discusses the current unmet needs in mantle cell lymphoma and how Bruton’s tyrosine kinase inhibitors are being looked at to fill that need for patients with high-risk disease in the first line.

Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.

Marcia Brose, MD, PhD, discusses how the thyroid cancer treatment landscape will be impacted by the positive findings regarding larotrectinib in the presence of a TRK fusion.

Matthew Davids, MD, MMSc, discusses the longer-term follow-up data from the phase 3 UNITY-CLL clinical trial, which evaluated umbralisib in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia.

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.

Srdan Verstovsek, MD, PhD, discusses the data seen in the phase 2 trial of CPI-0610 with or without ruxolitinib in patients with myelofibrosis.

Julie Gralow, MD, discusses the primary analysis of trastuzumab emtansine plus pertuzumab versus trastuzumab, pertuzumab, and taxane, after anthracyclines as adjuvant therapy in patients with high-risk HER2-positive early breast cancer in the of the KAITLIN study.

Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.

C. Ola Landgren, MD, PhD, discusses the use of chimeric antigen receptor T cells and CAR natural killer cells in the multiple myeloma setting.

Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.

Kenneth C. Anderson, MD, discusses the therapies for patients who have multiple myeloma and have developed drug resistance.

Vivek Subbiah, MD, discusses the frontline therapeutic options for patients with renal cell carcinoma.

Nilanjan Ghosh, MD, discusses the significance of the data from a pilot study of lisocabtagene maraleucel in patients ineligible for second-line transplant with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma.

Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib for lung cancer with ROS1 fusions and how to treat them.